Trial Profile

Phase Ia trial of RVX 208 in volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Apr 2009

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apabetalone (Primary)
Indications Acute coronary syndromes; Alzheimer's disease; Atherosclerosis; Low HDL cholesterol
Focus Adverse reactions

Most Recent Events

31 Mar 2009 Results presented at ACC 2009.
10 Nov 2008 Results presented at AHA 2008.
10 Nov 2008 Resverlogix has reported positive results of an exploratory analysis of effects on amyloid-beta levels.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com